Comparative analysis of seputinib versus platinib: which is the best choice for RET-targeted therapy?

Seputinib and platinib are both targeted therapeutic drugs targeting RET gene mutations. Both have their own characteristics, but in comparisons in many aspects, seputinib has shown its advantages.

From the perspective of its mechanism of action, seputinib is a reversible targeted drug that mainly achieves therapeutic effects by inhibiting the activity ofRETkinase, while platinib is an irreversible targeted drug that inhibitsRETkinase activity. pan>RET, ROS1 and ALK to exert therapeutic effects. This means that the effect of seputinib is more specific and may reduce unnecessary side effects.

In terms of efficacy, although the efficacy of the two in treatment-naïve patients is similar, seputinib shows a longer duration of progression-free survival (PFS), which means that patients can remain stable for a longer period of time after using seputinib. In addition, in terms of safety, seputinib also showed fewer serious adverse reactions, such as a lower incidence of grade 3 or above treatment-related adverse events (TRAEs).

Looking at drug resistance, the study found that the L730V/I RET mutation was resistant to platinib but sensitive to seputinib treatment. This suggests that seputinib may have a better therapeutic effect in the face of certain RET gene mutations.

The two drugs also differ in indications. The scope of application of seputinib seems to be wider. It can be used not only for RET fusion-positive non-small cell lung cancer, but also for other cancers related to RET mutations such as thyroid cancer. Platinib is mainly used for RET fusion-positive non-small cell lung cancer and thyroid cancer.

From the perspective of medication convenience, seputinib needs to be taken orally twice a day, while platinib only needs to be taken once a day, which may affect the patient's quality of life and compliance. However, this may be viewed as an acceptable trade-off given the superior efficacy and safety profile of seputinib.